Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2 ... EON: Enhanced Online News (press release) BOUDRY, Switzerland--(EON: Enhanced Online News)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from a randomized study comparing REVLIMID ® (lenalidomide) plus rituximab to lenalidomide ... Celgene Reveals Results From Revlimid Study For Recurrent Follicular Lymphoma Results from a Randomized Study of Celgene's REVLIMID and Rituximab in ... |
